Key result
Tryptophanyl-tRNA synthetase (WRS) is involved in various human diseases, including sepsis, cancer, autoimmune, and brain diseases, and represents a potential target for drug development.
Why the study?
WRS is generally regarded simply as an enzyme producing Trp, leaving studies of its pharmacological effects, therapeutic targets, and mechanisms of action at an emerging stage despite roles in multiple diseases.
Tryptophanyl-tRNA synthetase (WRS) has emerging potential as a therapeutic target for various pathological states including infection, tumorigenesis, and autoimmune and brain diseases.
Answers are grounded in this paper and cite their sources.
WRS may offer a new drug target across sepsis, cancer, and autoimmune diseases; leaves open validation in prospective trials.
during translation via aminoacylation. Interestingly, WRS also plays physiopathological roles in diseases including sepsis, cancer, and autoimmune and brain diseases and has potential as a pharmacological target and therapeutic. However, WRS is still generally regarded simply as an enzyme that produces Trp in polypeptides; therefore, studies of the pharmacological effects, therapeutic targets, and mechanisms of action of WRS are still at an emerging stage. This review summarizes the involvement of WRS in human diseases. We hope that this will encourage further investigation into WRS as a potential target for drug development in various pathological states including infection, tumorigenesis, and autoimmune and brain diseases.
No takes yet. Share an insight, caveat, or question.
Ahn et al. (2021) conducted a review in Sepsis, cancer, autoimmune and brain diseases. Tryptophanyl-tRNA Synthetase (WRS) targeting was evaluated. Tryptophanyl-tRNA synthetase (WRS) is involved in various human diseases, including sepsis, cancer, autoimmune, and brain diseases, and represents a potential target for drug development.
Synapse has enriched 10 related papers. Consider them for comparative context: